Feasibility Analysis and Medical Process Interpretation of Thalassemia IVF in Georgia

Real Consultation Scenario: A Question from an α-Thalassemia Carrier

In December 2024, a 28-year-old woman privately messaged asking: "My husband and I are both carriers of mild α-thalassemia. After domestic consultations, we were advised to undergo third-generation IVF (PGT-M), but the embryo biopsy at the local hospital requires a waiting list of over six months. A friend recommended Georgia, saying there is no waiting period and the cost is low. Can we really go to Georgia for this? What are the risks?"

This is a very typical consultation for genetic disease prevention. Thalassemia is a monogenic disorder. When both partners are carriers of the same type of thalassemia (α-α or β-β), there is a 25% chance of having a child with severe thalassemia. Georgia, as a popular destination for assisted reproduction in Eastern Europe, does allow PGT-M (Preimplantation Genetic Testing for Monogenic Disorders) technology, but patients must meet specific medical and regulatory conditions.

Direct Answer: Can Thalassemia Patients Undergo IVF in Georgia?

Yes, but with strict prerequisites. Georgian law permits genetic testing for monogenic disorders (PGT-M) on embryos using third-generation IVF technology, provided that patients can provide a clear genetic diagnosis report, chromosomal karyotype analysis of the couple, and the collaborating reproductive center in Georgia must have PGT-M laboratory qualifications. Currently, major IVF centers in Georgia (such as Georgian International Hospital, Alpha IVF, etc.) have PGT-A (chromosomal screening) capabilities, but the number of centers offering PGT-M services is limited and requires prior confirmation.

Why Do Thalassemia Patients Consider Georgia?

There are two core driving factors: waiting period and cost. In some domestic reproductive centers, the waiting period for a PGT-M cycle is 3-12 months, and the cost is usually 80,000-150,000 RMB (including embryo testing). The total cost for third-generation IVF in Georgia (ovarian stimulation, egg retrieval, embryo culture, biopsy, frozen embryo transfer) is approximately 50,000-80,000 RMB, with no long waiting times. However, it is important to note that PGT-M testing in Georgia typically requires sending embryo biopsy samples to third-party genetic laboratories (some in Cyprus or Greece), which adds an additional 2-3 weeks to the testing cycle.

Reproductive Doctor's Decision Logic: Who is Suitable? Who is Absolutely Unsuitable?

Suitable Candidates:

• Couples diagnosed as carriers of the same type of thalassemia (α-thalassemia or β-thalassemia) through genetic testing;
• Female partner has normal ovarian reserve (AMH ≥ 1.2 ng/mL, antral follicle count ≥ 6), capable of producing at least 5-8 eggs for embryo biopsy;
• No other uncontrolled reproductive system diseases (e.g., severe intrauterine adhesions, endometrial tuberculosis);
• Willing to accept frozen embryo transfer (PGT-M testing usually requires biopsy after 5-6 days of culture, then freezing while awaiting results).

Absolutely Unsuitable Candidates:

• One partner has severe thalassemia (severe anemia requiring lifelong blood transfusions) — such patients often have secondary infertility or organ damage and need treatment for the primary disease first;
• Female partner has severely diminished ovarian function (AMH < 0.5 ng/mL) — too few embryos may not yield sufficient biopsy samples;
• Couples who have not completed formal genetic counseling and obtained a signed consent form from the hospital;
• Those with concerns about Georgian law or embryo transfer policies (Georgia does not allow sex selection for non-medical reasons, but PGT-M screening is medically permitted).

Easily Overlooked Detail: Essential Preparations Before PGT-M Testing

Many patients think they can go directly to Georgia for IVF with just their domestic genetic report. In the actual process, Georgian reproductive centers will require a new genetic counseling session and local doctors will review the domestic report. If the domestic report only indicates "α-thalassemia gene deletion" without specific typing (e.g., --SEA, -α3.7, etc.), supplementary testing may be needed. Additionally, the male partner must also complete a semen analysis (Georgia requires a report within 6 months). If there is severe sperm DNA fragmentation (DFI > 30%), it will directly affect the success rate of embryo biopsy.

Another key point is passport validity. It is recommended to ensure the passport has a remaining validity of more than 6 months before travel, because embryos need to be stored frozen for at least 3 months. Some patients may require a second transfer due to different endometrial conditions in the same month, and Georgia allows embryo cryopreservation for up to 5 years, so the passport must remain valid within this time frame.

Policy Differences Across Countries: Why Georgia is Feasible While Others May Be Restricted?

It can be seen that Georgia's core advantages are low cost and no waiting list, but the disadvantage is that the PGT-M process requires external shipping, and some centers have less experience with monogenic disease testing compared to the US or Thailand. Therefore, when choosing Georgia, it is essential to request the agency or hospital to provide qualification certificates of the collaborating genetic laboratory.

Common Pitfall: Agencies Hiding "Embryo Biopsy Failure Rate"

During the PGT-M process, approximately 10-20% of embryos cannot undergo biopsy or testing (due to developmental arrest, insufficient biopsy cell number, or laboratory technical errors). Many agencies advertise a "99% success rate in preventing thalassemia," which actually refers to the accuracy of preventing the disease after transplantation of a normal embryo. However, patients need to understand: not every cycle will yield a healthy embryo suitable for transfer. For example, if the female partner is ≥38 years old, retrieving 10 eggs may result in only 2-3 blastocysts meeting biopsy criteria. If only one passes PGT-M and is a normal embryo, the subsequent transfer success rate is only about 50-60%. Therefore, being prepared for multiple cycles is crucial.

Another common trap is that some Georgian centers quote PGT-A (chromosomal screening) as PGT-M to patients. Embryos from thalassemia patients must undergo PGT-M (monogenic testing), not just chromosomal number screening. Before testing, it is essential to confirm that the laboratory uses multiple displacement amplification (MDA) or whole genome amplification followed by specific probe detection, rather than just low-depth copy number variation analysis using NGS.

Actual Process and Timeline

1. Step 1: Preliminary Preparation (1-2 months): Complete the latest genetic typing verification, blood routine, hemoglobin electrophoresis, ferritin, AMH, FSH, semen analysis, chromosomal karyotype, and infectious disease tests in your home country. Also, apply for a passport (if remaining validity is less than 6 months, renew it).
2. Step 2: Remote Consultation and Hospital Selection (1-2 weeks): Contact Georgian reproductive centers via their official website or an agency, send all test reports, confirm the center's PGT-M capability and its collaborating genetic laboratory. Request a written quotation.
3. Step 3: Menstrual Regulation and Travel Arrangements (1 month): The female partner may need to take progesterone or short-acting contraceptives to ensure a controllable menstrual cycle. Book flights and accommodation (recommended stay of at least 25-30 days, covering stimulation to egg retrieval and embryo culture).
4. Step 4: Ovarian Stimulation and Egg Retrieval (approximately 12-15 days): Start stimulation upon arrival in Georgia, with hormone tests and vaginal ultrasounds every 2-3 days. Egg retrieval is performed under painless intravenous anesthesia, taking about 20 minutes.
5. Step 5: Embryo Culture and Biopsy (5-7 days): After egg retrieval, eggs and sperm are combined and cultured to the blastocyst stage on day 5-6. An embryologist biopsies 3-5 trophectoderm cells, and the embryos are then vitrified and frozen.
6. Step 6: Genetic Testing and Report (3-4 weeks): Biopsy samples are air-shipped to the designated genetic laboratory for monogenic disease testing. After results are available, patients communicate online with a genetic counselor to confirm which embryos are normal and which are carriers.
7. Step 7: Frozen Embryo Transfer (1-day procedure + 12-day wait): Endometrial preparation is done according to the patient's menstrual cycle. Transfer occurs on day 5 after ovulation or on day 18-20 of an artificial cycle. Blood HCG test is performed 12 days after transfer.

Total Time Commitment: From initial preparation to completion of transfer, it takes approximately 4-6 months (including two menstrual cycles). If the first transfer fails, a second frozen embryo can be transferred directly without another stimulation cycle.

Factors Affecting Thalassemia IVF Success Rates

We do not promise specific success rates, but we can clearly tell you the key indicators that affect success:

• Female Age: Under 35, 35-38, and over 38 years old — the rate of chromosomal abnormalities in eggs increases with age, directly reducing the number of normal embryos available for PGT-M.
• Thalassemia Type: Patients with β-thalassemia combined with α-thalassemia have a higher probability of multiple abnormalities in embryos, requiring more complex linkage analysis.
• Embryology Lab Quality: Some Georgian centers have newer equipment, but staff experience may be less than that of large international centers. You can request the center's blastocyst formation rate for the past year (≥55% is considered qualified).
• Genetic Lab Testing Efficiency: If the external lab's testing cycle is too long (over 5 weeks), embryo quality may be affected by storage time (though vitrification for up to 5 years has minimal impact).

Practitioner's Observation: Why Some Patients Are Not Suitable for This Plan?

As an assisted reproduction consultant with 10 years of experience, I have seen many thalassemia patients rush to Georgia and then give up midway. Common reasons include: ① Not understanding that the miscarriage rate for PGT-M tested frozen embryos is not significantly different from fresh embryos, but the quality requirements for embryo biopsy are high; ② Language barriers leading to misunderstandings when interpreting genetic results; ③ Limited channels for medical dispute resolution in Georgia — if test results are erroneous (e.g., misclassifying a normal embryo as a thalassemia carrier), the cost of seeking redress is high. Therefore, it is strongly recommended to complete the following before departure:

• Ask a geneticist in your home country to review the PGT-M plan from the Georgian hospital;
• Request the hospital to provide a service description regarding "whether remaining cells after embryo biopsy can be used for secondary verification";
• Confirm whether the hospital participates in international genetic external quality assessment schemes (e.g., EMQN, CAP accreditation).

Risk Reminder

The IVF industry in Georgia has developed rapidly in recent years, but the regulatory system is relatively lagging. In 2024, media reported cases of misdiagnosis in some small clinics using unverified PGT reagents. Therefore, it is not recommended to choose clinics that cannot provide clear genetic test reports or disclose the qualifications of their collaborating laboratories. Additionally, all authorizations regarding embryo fate must be signed in a Chinese translation version to prevent embryos from being discarded or used for unintended purposes due to language ambiguity. If you fall into the following categories: female age ≥40, significantly diminished ovarian function, or a history of repeated IVF failures, it is preferable to undergo PGT-M in your home country, the United States, or Thailand, rather than choosing Georgia.

This article has been reviewed by the Reproductive Medicine Knowledge Base Editorial Board and does not constitute medical advice. Please consult your primary physician for specific treatment plans.